Pfizer Price to Sales Ratio 2012-2025 | PFE
Historical PS ratio values for Pfizer (PFE) over the last 10 years. The current P/S ratio for Pfizer as of March 09, 2026 is .
| Pfizer P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-03-09 | 26.81 | 2.44 | |
| 2025-12-31 | 24.49 | $10.97 | 2.23 |
| 2025-09-30 | 24.63 | $11.00 | 2.24 |
| 2025-06-30 | 23.03 | $11.19 | 2.06 |
| 2025-03-31 | 23.63 | $10.95 | 2.16 |
| 2024-12-31 | 24.33 | $11.16 | 2.18 |
| 2024-09-30 | 26.14 | $10.60 | 2.47 |
| 2024-06-30 | 24.92 | $9.89 | 2.52 |
| 2024-03-31 | 24.35 | $9.83 | 2.48 |
| 2023-12-31 | 24.88 | $10.45 | 2.38 |
| 2023-09-30 | 28.29 | $12.28 | 2.30 |
| 2023-06-30 | 30.94 | $13.85 | 2.23 |
| 2023-03-31 | 34.04 | $16.43 | 2.07 |
| 2022-12-31 | 42.37 | $17.66 | 2.40 |
| 2022-09-30 | 35.87 | $17.45 | 2.06 |
| 2022-06-30 | 42.65 | $17.69 | 2.41 |
| 2022-03-31 | 41.77 | $16.16 | 2.59 |
| 2021-12-31 | 47.29 | $14.27 | 3.31 |
| 2021-09-30 | 34.14 | $12.12 | 2.82 |
| 2021-06-30 | 30.81 | $9.75 | 3.16 |
| 2021-03-31 | 28.22 | $8.17 | 3.45 |
| 2020-12-31 | 28.37 | $7.41 | 3.83 |
| 2020-09-30 | 26.56 | $5.70 | 4.66 |
| 2020-06-30 | 23.44 | $6.12 | 3.83 |
| 2020-03-31 | 23.16 | $6.70 | 3.45 |
| 2019-12-31 | 27.52 | $7.19 | 3.83 |
| 2019-09-30 | 25.00 | $7.06 | 3.54 |
| 2019-06-30 | 29.86 | $7.03 | 4.24 |
| 2019-03-31 | 29.02 | $6.96 | 4.17 |
| 2018-12-31 | 29.57 | $6.81 | 4.34 |
| 2018-09-30 | 29.62 | $8.88 | 3.34 |
| 2018-06-30 | 24.18 | $8.83 | 2.74 |
| 2018-03-31 | 23.42 | $8.71 | 2.69 |
| 2017-12-31 | 23.69 | $8.68 | 2.73 |
| 2017-09-30 | 23.14 | $8.63 | 2.68 |
| 2017-06-30 | 21.56 | $8.57 | 2.52 |
| 2017-03-31 | 21.74 | $8.57 | 2.54 |
| 2016-12-31 | 20.44 | $8.56 | 2.39 |
| 2016-09-30 | 21.10 | $8.59 | 2.46 |
| 2016-06-30 | 21.75 | $8.41 | 2.59 |
| 2016-03-31 | 18.15 | $8.17 | 2.22 |
| 2015-12-31 | 19.57 | $7.81 | 2.51 |
| 2015-09-30 | 18.89 | $7.60 | 2.48 |
| 2015-06-30 | 20.01 | $7.60 | 2.63 |
| 2015-03-31 | 20.59 | $7.68 | 2.68 |
| 2014-12-31 | 18.28 | $7.71 | 2.37 |
| 2014-09-30 | 17.20 | $7.63 | 2.25 |
| 2014-06-30 | 17.11 | $7.60 | 2.25 |
| 2014-03-31 | 18.36 | $7.44 | 2.47 |
| 2013-12-31 | 17.36 | $7.40 | 2.35 |
| 2013-09-30 | 16.16 | $7.14 | 2.26 |
| 2013-06-30 | 15.63 | $6.97 | 2.24 |
| 2013-03-31 | 15.97 | $7.00 | 2.28 |
| 2012-12-31 | 13.75 | $7.25 | 1.90 |
| 2012-09-30 | 13.51 | $6.99 | 1.93 |
| 2012-06-30 | 12.39 | $7.39 | 1.68 |
| 2012-03-31 | 12.08 | $7.62 | 1.59 |
| 2011-12-31 | 11.42 | $7.71 | 1.48 |
| 2011-09-30 | 9.24 | $8.17 | 1.13 |
| 2011-06-30 | 10.65 | $8.03 | 1.33 |
| 2011-03-31 | 10.40 | $8.08 | 1.29 |
| 2010-12-31 | 8.87 | $8.07 | 1.10 |
| 2010-09-30 | 8.61 | $8.40 | 1.03 |
| 2010-06-30 | 7.07 | $8.13 | 0.87 |
| 2010-03-31 | 8.41 | $7.63 | 1.10 |
| 2009-12-31 | 8.84 | $7.20 | 1.23 |
| 2009-09-30 | 7.97 | $6.78 | 1.17 |
| 2009-06-30 | 7.15 | $6.84 | 1.04 |
| 2009-03-31 | 6.42 | $7.01 | 0.92 |
| 2008-12-31 | 8.17 | $7.16 | 1.14 |
| 2008-09-30 | 8.36 | $7.18 | 1.16 |
| 2008-06-30 | 7.79 | $7.14 | 1.09 |
| 2008-03-31 | 9.19 | $6.93 | 1.33 |
| 2007-12-31 | 9.84 | $6.94 | 1.42 |
| 2007-09-30 | 10.45 | $6.82 | 1.53 |
| 2007-06-30 | 10.80 | $6.77 | 1.59 |
| 2007-03-31 | 10.56 | $6.80 | 1.55 |
| 2006-12-31 | 10.71 | $6.63 | 1.62 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $156.812B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |